EANS-News: november Aktiengesellschaft / PROGEN and Mitsubishi Chemical Europe GmbH Sign an Exclusive Distribution Contract for the PATHFAST® POCT Analyzing System

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

New Products/Research & Development

Köln (euro adhoc) - Effective immediately, PROGEN Biotechnik GmbH, a
subsidiary of november AG, exclusively distributes the PATHFAST®
analyzing system of Mitsubishi Chemical Europe GmbH in Germany. The
PATHFAST® analyzing system enables effective parallel processing of
up to six patient samples or analytes in one run. High precision as
well as a fast and easy-to-perform test procedure makes the PATHFAST®
the ideal analyzing system on a cardiology, intensive care or an
emergency ward, as an adequate 'outpost' of a central laboratory. The
PATHFAST® analyzing system allows quantitative and reliable
measurements from heparin or EDTA whole blood or plasma in emergency
medicine (e.g. myocardial infarction, myocarditis). Available cardiac
markers are Troponin I, CK-MB mass, Myoglobin, NT-proBNP as well as
hsCRP.

Features of the PATHFAST® analyzing system: • meets the guideline of
the German Cardiac Society (DKG, BNK) for a CV <10% at the 99%
percentile for Troponin measurement • profile of cardiac markers
(e.g. cTnI, CK-MB, NT-proBNP) in one test run • analysis from heparin
or EDTA whole blood or plasma • simultaneous analysis of up to six
samples or analytes • results in 17 minutes • integrated computer and
printer, touch screen operation • barcode reader, RS-232C interface,
LIMS connection, data transfer • no water connection and buffer
system required • ready-to-use cartridge including all reagents and
buffer • only one cartridge and one pipette tip per test run • no
training required • attractive leasing offers

With the takeover of the distribution of the PATHFAST® analyzing
system, november´s subsidiary PROGEN is expanding its product range
in the area of emergency diagnostics. This high-quality analyzing
system is an ideal supplement to PROGEN´s own product range which
adds growth potential and supports PROGEN´s growth strategy and will
contribute to increase sales turnovers.

About november AG/PROGEN Biotechnik GmbH november AG, Cologne, is an
investment and holding company, listed in the prime standard of the
regulated market of the German stock exchange (Deutsche Böse) with
special focus on medical technology, biotechnology and environmental
technology. november AG is 100% shareholder of PROGEN Biotechnik
GmbH, Heidelberg. PROGEN is a DIN EN ISO 13485:2007 certified
manufacturer of in vitro diagnostics (e.g. Borrelia, Hantavirus,
FSME) and research reagents (e.g. antibodies, polypeptides, AAV,
hyperphage) as well as specialist in the manufacturing of multiplex
assays based on the Luminex® platform. PROGEN is member of the VDGH
(German Association of Diagnostic Manufacturers).

About Mitsubishi Chemical Europe GmbH (PATHFAST®) Mitsubishi Chemical
Europe GmbH and Mitsubishi Chemical Medience Corporation are a
subsidiaries of Mitsubishi Chemical Corporation. The core business of
Mitsubishi Chemical Medience comprises the development, production
and distribution of analysis devices and reagents for fast and
accurate emergency diagnosis.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: november Aktiengesellschaft
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Dirk Zurek
Tel.: +49 (0) 221 820 05 20 10
E-mail: ir@november.de

Branche: Biotechnology
ISIN: DE000A0Z24E9
WKN: A0Z24E
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade